Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Sage Therapeutics news
03.05.2022
Sage Therapeutics' GAAP loss for 3 months of 2022 was $122.055 million, up 27.5% from $95.764 million in the prior year. Revenue decreased 0.1% to $1,582 million from $1,583 million a year earlier.
Source: 
investor.sagerx.com
investor.sagerx.com
24.02.2022
Sage Therapeutics reported a GAAP loss of $457.892 million for 2021, compared to a profit of $606.073 million in the previous year. Revenue declined 18.6 times to $0.06 billion from $1.114 billion a year earlier.
Source: investor.sagerx.com
investor.sagerx.com
02.11.2021
Sage Therapeutics' GAAP loss for 9M 2021 was $333.18 million, down 9.7% from $368.822 million in the prior year. Revenues fell 6.9% to $4.666 million from $5.014 million a year earlier.
Source: investor.sagerx.com
investor.sagerx.com
03.08.2021
Sage Therapeutics' GAAP loss for the six months of 2021 was $203.009 million, down 22.8% from $263.087 million in the prior year. Revenue declined 4.4% to $3.226 billion from $3.375 billion a year earlier.
Source: investor.sagerx.com
investor.sagerx.com
General information
| Company name | Sage Therapeutics |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380 |
| Mailing address | 215 FIRST STREET CAMBRIDGE MA 02142 |
| Website | www.sagerx.com |
| Information disclosure | www.sec.gov |
English (US) 